STI571 (imatinib mesylate): The tale of a targeted therapy

Anti-Cancer Drugs

Volumn 13, Issue 2, 2002, Pages 111-114

  Thambi, Paul ^a   Sausville, Edward A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Imatinib mesylate; STI571; Targeted therapy

Indexed keywords

BCR ABL PROTEIN; HYBRID PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR;

BLOOD DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG RESISTANCE; DRUG TARGETING; EDEMA; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0036189039     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200202000-00001     Document Type: Review

References (28)

1. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia
2. The story of chronic myeloid leukemia
3. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
4. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
5. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cell expressing Bcr-Abl, Tel-Abl, and Tel-PDGFR fusion proteins
6. Inhibition of c-kit tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor
7. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl-positive cells
8. Selective inhibition of cell proliferation and Bcr-Abl phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 Bcr-Abl protein by a tyrosine kinase inhibitor (CGP-57148)
9. STI571: Targeting Bcr-Abl as therapy for CML
10. In vivo eradication of human Bcr/Abl-positive leukemia cells with an Abl kinase inhibitor
11. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia
12. Cutaneous reactions to STI571
13. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
14. Cancer treatment in the STI571 era: What will change?
15. Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification
16. Role of alpha 1 acid glycoprotein in the in vivo resistance of human Bcr-Abl + leukemic cells to the Abl inhibitor STI571
17. Dragons round the fleece again: STI571 vs alpha 1 acid glycoprotein
18. Classes of c-kit activating mutations: Proposed mechanisms of action and implications for disease classification and therapy
19. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
20. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
21. Intracranial inhibition of platelet derived growth factor mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class
22. Blockade of PDGF-R signaling by STI571 inhibits angiogenesis and growth of human prostate cancer cells in the bone of nude mice
23. New targets for cancer chemotherapy: STI571 (Gleevec)